

New mutation linked to non-Hodgkin's lymphoma

1 November 2010

Some patients with non-Hodgkin lymphoma (NHL) -- a cancer of B cells -- harbor a particular mutation in the gene encoding the receptor for B cell activating factor (BAFF), according to a paper published online on November 1 in the *Journal of Experimental Medicine*. BAFF, a soluble protein needed for B cell survival and maturation, is elevated in the blood of some NHL patients and is associated with poor prognosis.

This BAFF-R mutation, identified by a team led by Anne Novak and Gail Bishop, generates a receptor that transmits stronger than normal signals, thus boosting [B cell](#) function.

Although present in fewer than 10% of the tumors analyzed in the study, this mutation provides further evidence of the importance of BAFF signaling in this dangerous malignancy.

More information: Hildebrand, J.M., et al. 2010. *J. Exp. Med.* [doi:10.1084/jem.20100857](https://doi.org/10.1084/jem.20100857)

Provided by Rockefeller University

APA citation: New mutation linked to non-Hodgkin's lymphoma (2010, November 1) retrieved 23 April 2021 from <https://medicalxpress.com/news/2010-11-mutation-linked-non-hodgkin-lymphoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.